All In Biotech

NDA 019012 · Kenvue Brands

Motrin Migraine Pain

Ibuprofen · Oral

Last checked: Nov 19, 2026Latest source record: Nov 16, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1984

May 18, 1984

Approved uses

2

Original approval plus efficacy supplements

Registered trials

910

162 Phase 3, 61 recruiting

FAERS reports

204,237

147,624 serious, 16,517 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 1, 2026.

Uses ■ temporarily relieves minor aches and pains due to: ■ headache ■ muscular aches ■ minor pain of arthritis ■ toothache ■ backache ■ the common cold ■ menstrual cramps ■ temporarily reduces fever

Therapeutic areas: Neurology · Pain and anesthesia

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 25, 2000 Supplement 16 · Efficacy ReviewLabelLetter
  • May 18, 1984 Original approval · Type 5 - New Formulation or New Manufacturer
4 products under this application
  • MOTRIN MIGRAINE PAIN · IBUPROFEN 200MG · TABLET, ORAL · Discontinued
  • NUPRIN · IBUPROFEN 200MG · TABLET, ORAL · Discontinued
  • MOTRIN IB · IBUPROFEN 200MG · TABLET, ORAL · Over-the-counter
  • NUPRIN · IBUPROFEN 200MG · TABLET, ORAL · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Ibuprofen" as an intervention, any sponsor and status, largest first.

All 910 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective16,234
  • pain15,332
  • fatigue14,852
  • nausea13,890
  • headache12,362
  • arthralgia11,136
  • dyspnoea10,768
  • vomiting10,215
  • diarrhoea9,998
  • rash9,216
  • off label use8,901
  • dizziness8,394

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,624
20052,146
20062,063
20072,132
20081,796
20092,780
20104,073
20115,736
20127,117
20136,888
20146,624
20159,398
201612,803
201711,574
201815,839
201916,886
202015,651
202115,408
202214,826
202313,927
202412,845
202512,993
20269,099

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,679 on PubMed

Sponsor: Kenvue Brands · Also marketed as Nuprin, Motrin Ib

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.